1834 Investment Advisors Co. Sells 540 Shares of Edwards Lifesciences Co. (NYSE:EW)

1834 Investment Advisors Co. reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,678 shares of the medical research company’s stock after selling 540 shares during the period. 1834 Investment Advisors Co.’s holdings in Edwards Lifesciences were worth $642,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Edwards Lifesciences by 42.9% during the second quarter. EverSource Wealth Advisors LLC now owns 932 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 280 shares during the last quarter. Public Sector Pension Investment Board raised its holdings in Edwards Lifesciences by 73.6% in the second quarter. Public Sector Pension Investment Board now owns 23,267 shares of the medical research company’s stock worth $2,149,000 after purchasing an additional 9,863 shares during the period. APG Asset Management N.V. raised its stake in Edwards Lifesciences by 2.9% during the 2nd quarter. APG Asset Management N.V. now owns 492,537 shares of the medical research company’s stock worth $42,450,000 after buying an additional 13,832 shares during the period. Daymark Wealth Partners LLC lifted its holdings in shares of Edwards Lifesciences by 8.3% during the 2nd quarter. Daymark Wealth Partners LLC now owns 8,533 shares of the medical research company’s stock valued at $788,000 after purchasing an additional 656 shares in the last quarter. Finally, MBB Public Markets I LLC acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $4,055,000. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.1 %

NYSE EW opened at $68.98 on Friday. The business’s fifty day moving average is $72.33 and its 200-day moving average is $70.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $40.68 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 3.54 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the company earned $0.59 earnings per share. The company’s quarterly revenue was up 8.9% on a year-over-year basis. Equities research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Canaccord Genuity Group raised their price objective on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Barclays boosted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Finally, Truist Financial reissued a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.